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Introduction: Inflammation has been implicated in cancer aggressiveness. As transglutaminase 2 (TG2), which has
been associated with inflammatory signaling, has been suggested to play a role in tumor behavior, we propose
that TG2 may be an important linker inducing interleukin (IL)-6-mediated cancer-cell aggressiveness, including
distant hematogenous metastasis.
Methods: To investigate the role for TG2 and IL-6, TG2-knocked-down and IL-6-knocked-down cancer cells were
generated by using shRNA. Human breast cancer cell xenograft model in highly immunocompromised mice and
human advanced breast cancer primary tumor tissue microarrays were used in this study.
Results: IL-6 production in human breast cancer cells was dependent on their TG2 expression level. In vitro tumor-
sphere formation was dependent on TG2 and downstream IL-6 production from cancer cells. Primary tumor growth
in the mammary fat pads and distant hematogenous metastasis into the lung was also dependent on TG2 and
downstream IL-6 expression levels. The effect of TG2 expression on human breast cancer distant metastasis was
investigated by analyzing a tissue microarray of primary tumors from 412 patients with their clinical data after 7 years.
TG2 expression in primary tumor tissue was inversely correlated with recurrence-free survival (P = 0.019) and distant
metastasis-free survival (DMFS) (P = 0.006) in patients with advanced breast cancer. Furthermore, by using public
datasets that included a total of 684 breast cancer patients, we found that the combined high expression of TG2 and
IL-6 was associated with shorter DMFS, compared with the high expression of IL-6 only (P = 0.013).
Conclusions: We provide evidence that TG2 is an important link in IL-6-mediated tumor aggressiveness, and that
TG2 could be an important mediator of distant metastasis, both in a xenograft animal model and in patients with
advanced breast cancer.
Introduction
Immune/inflammatory responses have largely been con-
sidered a key protective mechanism of hosts against
growing tumor cells [1]. However, inflammation is now
also recognized to be important in the pathogenesis of
many types of malignancies [2]. Persistent Helicobacter
pylori infection is associated with gastric cancer [3].
Viral infections lead to chronic inflammation and are
responsible for the majority of hepatocellular
carcinomas [4]. Obesity also promotes chronic inflam-
mation and results in a substantial increase in cancer
risk in the liver [5] and pancreas [6].
Inflammation thus triggered by infection, obesity, or
the tumor itself recruits inflammatory cells to the
tumor-stroma interface, and these cells, together with
the tumor cells, generate a microenvironment capable of
driving tumor progression [7]. The concerted action of
inflammatory cytokines, together with oxidative stress
and hypoxia in the tumor environment converge to acti-
vate nuclear factor (NF)-B in cancer cells [8]. NF-B
signaling has been implicated in several cancer cell
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malignant conversion, invasion, and metastasis [9].
Interleukin (IL)-6 is an important downstream effector
of NF-B. High serum IL-6 levels correlate with poor
disease outcome and reduced clinical prognosis in
patients with breast, lung, and liver cancer [10,11] and
with cancer formation in a murine colitis-associated
colon cancer model [12]. IL-6, produced from bone
marrow-derived cells, promotes growth of tumor-initiat-
ing cells during early tumorigenesis and protects these
cells from apoptosis [12]. Furthermore, IL-6 produced in
epithelial cancer cells themselves plays an important role
in tumor growth and metastasis, in an autocrine and/or
paracrine manner. IL-6 signaling pathways in epithelial
cancer cells have also been linked to in vivo aggressive-
ness by affecting epithelial-to-mesenchymal conversion
[13,14] or conferring the cancer stem cell-like properties
of these cells [15]. The molecular links leading to IL-6
production in epithelial cancer cells, which are corre-
lated with distant metastasis and cancer stem cell-like
properties, are currently under active investigation. Non-
infectious stimuli activating the IL-6 signaling pathway
lead to fibrosis through transglutaminase 2 (TG2) in
pulmonary epithelial cells (unpublished data). As fibrosis
and invasion of cancer have common characteristics
[16], we propose that TG2 expressed in epithelial cancer
cells might provide a similar connection.
TG2 has been implicated in the drug resistance and
survival of cancer cells by modulating caspase-3 and
NF-B activity [17-20] and in the in vitro migration and
invasion of tumor cells through increased cell attach-
ment via b-integrins and fibronectins with extracellular
TG2 [21-23] and increases in matrix metalloprotease-2
(MMP-2) expression [24]. Peritoneal spreading of ovar-
ian cancer cells [25] and tumor growth of pancreatic
cancer [26] also parallel TG2 expression levels. Recently,
correlation of TG2 expression and epithelial-to-
mesenchymal transition and invasion of cancer cells
were reported for both breast and ovarian cancer cells
[27,28]. However, a direct link between TG2 expression
of primary tumors and distant hematogenous metastasis
in animal models and cancer patients and cancer stem
cell-like properties, which are related to cancer cell
aggressiveness, has not been made.
In this study, we demonstrated that TG2 expression
levels are correlated with cancer cell aggressiveness, and
that the size and efficiency of tumor sphere formation
was correlated with TG2 expression levels and was
dependent on TG2-mediated IL-6 secretion in breast
cancer cells. With highly immunocompromised mice,
we evaluated the critical role of TG2 and downstream
IL-6 in the distant metastasis of breast cancer cells.
Moreover, TG2 expression in primary tumor tissue was
inversely correlated with recurrence-free survival and
distant metastasis-free survival (DMFS) in patients with
breast cancer, evaluated from a tissue microarray of pri-
mary tumors. Furthermore, by using public datasets that
included a total of 684 breast cancer patients, we found
that the expression of TG2 and IL-6 was correlated in
breast cancer patients and that the combined high
expression of TG2 and IL-6 was related to a poor
DMFS outcome in breast cancer. Thus, in this study, we
provide evidence that TG2 is an important link in IL-6-
mediated tumor aggressiveness and that TG2 could be
an important mediator of distant metastasis in both a
xenograft animal model and in patients with advanced
breast cancer.
Materials and methods
Cell lines and TG2- and IL-6-knockdown
The human breast cancer cell lines were obtained from
the American Type Culture Collection (Manassas, VA,
USA). TG2-knocked-down MDA-MB-231 cells
(shTG2_MB231) were established by using the short-
hairpin RNA (shRNA) vector for TG2. The target
sequence for TG2 was 5’-GGGCGAACCACC TGAA-
CAA-3’ [29]. In brief, MDA-MB-231 cells were co-trans-
fected with the pcDNA3.1 plus pSUPER plasmid
containing shRNA for TG2 by using Promofectin (Pro-
moKine, Heidelberg, Germany), according to the manu-
facturer’s instructions. Control cells were transfected
with the pcDNA3.1 vector only. TG2-knockdown in
selected clones was shown by Western blot analysis. IL-
6 production in MDA-MB-231 cells was inhibited by
using the IL-6 shRNA vector (shIL-6). Cells transfected
with the shIL-6 vector were cultured in the presence of
G418, and IL-6-knocked-down MDA-MB-231 (shIL-
6_MB231) clones were selected by performing an IL-6
enzyme-linked immunosorbent assay (ELISA).
Western blot analysis
Cells were harvested in a lysis solution containing 1%
NP40, a protease inhibitor cocktail, and a phosphatase
inhibitor (Sigma-Aldrich///). Proteins (10 μg) were sepa-
rated with SDS-PAGE, and transferred polyvinylidene
difluoride membranes were probed with appropriate
antibodies: anti-TG2 (Neomarkers, Fremont, CA, USA),
anti-b-actin (Sigma-Aldrich), anti-Bcl-2, and anti-cIAP2
(Santa Cruz Biotechnology, Santa Cruz, CA, USA).
ELISA and MTT assay
In total, 1 × 10
4 cells were applied on 24-well plates and
allowed to adhere overnight. Then the medium was
replaced, and cells were permitted to grow for 24, 48, or
72 hours. To inhibit TG2 activity, some cells were trea-
ted with cysteamine (Sigma-Aldrich). Supernatants were
collected and assayed to quantify soluble IL-6 produc-
tion by ELISA. All assays were performed in triplicate
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ditions. Data are presented as mean ± SD.
Sphere formation
Cells grown in an anchorage-independent condition
were trypsinized and resuspended in serum-free medium
consisting of a 1:1 mixture of F-12 Nutrient Mixture
(Ham’s F-12) and DMEM, supplemented with 20 ng/ml
epithelial growth factor (Invitrogen, Carlsbad, CA, USA),
20 ng/ml basic fibroblast growth factor (Millipore, Bill-
erica, MA, USA), 0.5 nM hydrocortisone (Sigma-
Aldrich), B-27 supplement (GIBCO), and 2 mM L-gluta-
mine (GIBCO///). Cells were applied on nonadherent
96-well plates (Corning, Corning, NY, USA) at 10, 100,
or 1,000 cells/100 μl/well. To inhibit TG2 activity, cells
were treated with cysteamine///. The medium was
replaced every 3 days. Visible spheres were counted
under a microscope on day 8 after plating.
Animals and xenografts
All mice were bred and maintained in specific pathogen-
free conditions at the animal facility of Seoul National
University College of Medicine. All animal experiments
were performed with the approval of the institutional
animal care and use committee of Seoul National
University.
To assess tumorigenicity of the cancer cells, human
breast cancer MDA-MB-231 cells were injected into the
mammary fatpads into 8-week-old NOD/scid/IL-2Rg
-/-
(NOG) mice (Jackson Laboratory, Bar Harbor, ME,
USA). Six weeks after the injection, the mice were killed,
and primary tumor masses in the fatpads for breast can-
cer and lung were fixed in 4% paraformaldehyde for 24
hours. Sections (4 μm) were stained with hematoxylin
and eosin. The number of tumor masses in the liver and
lung were counted under a dissecting microscope.
Tissue microarray and immunohistochemistry
To investigate the clinical significance of TG2 expres-
sion in human breast cancer tissue, TG2 expression was
evaluated by immunohistochemistry in a tissue microar-
ray. The tissue microarray was constructed from repre-
sentative paraffin-embedded tumor tissues by an
experienced breast pathologist. The array consisted of
two cores per patient. The tissue microarray slides were
stained with anti-TG2 (1:100, Neomarkers////). Antigen
retrieval was facilitated by microwaving the tissue for 21
minutes, and the remainder of the staining procedure
followed the standard avidin-biotinylated peroxidase
complex method by using a commercial immunohisto-
chemical kit (Envision-Kit; Dako, Carpinteria, CA, USA).
The TG2 expression level in tumor tissue was deter-
mined by comparison with the TG2 expression in nor-
mal endothelial cells. Immunohistochemical staining was
interpreted and categorized with an arbitrary semiquan-
titative scale as 0 (negative staining), 1+ (equivalent to
normal endothelial cell expression), and 2+ (more than
normal endothelial cell expression) by a pathologist.
Tumors showing TG2 expression (score, 2+) were cate-
gorized into a strong-TG2 group, and tumors showing 0
or 1+ TG2 expression, into a negative/weak-TG2 group
for further statistical analysis. This study was approved
by the Seoul National University Hospital institutional
review board.
Analysis of public human breast cancer gene expression
datasets
We collected three public mRNA expression datasets
comprising a total of 684 breast cancer patients (GEO
accession numbers: [GSE7390], [GSE11121], and
[GSE2034]) [30-32]. The raw data were normalized by
using the RMA approach, and final log2-transformed
data were used for further analyses. Clinical data were
d o w n l o a d e df r o mt h es a m es i t e .T h el e v e lo fT G 2
expression was calculated by averaging the expression
values of three probe sets (211003_x_at, 211573_x_at,
and 216183_at). Survival was analyzed based on distant
metastasis-free survival (DMFS) by using Kaplan-Meier
curves and the log-rank test.
Statistical analyses
The IL-6 production and cell-viability results are
expressed as mean ± SD. A two-tailed Student t test
was used to compare measurements taken from the two
samples. For in vivo experiments, differences in the
numbers of tumor masses and tumor volume were ana-
l y z e db yu s i n gat w o - t a i l e dS t u d e n tt test. A two-tailed
c
2 test and Student t test were used to compare nominal
and continuous variables of the TG2 expression groups
in the human breast cancer tissue microarray. Univariate
survival analysis was performed with a Kaplan-Meier
curve and the log-rank test. The Cox proportional
hazard model was used for the survival analysis. All P
values < 0.05 were deemed to indicate statistical signifi-
cance. The SPSS software (ver. 11.0; SPSS Inc., Chicago,
IL, USA) was used for all statistical analyses.
Results
TG2 expression levels correlated with IL-6 production
To evaluate the correlation between TG2 expression and
biologic characteristics of cancer cells, we first analyzed
TG2 expression in various human breast cancer cells
encompassing luminal, basal A, and basal B types,
according to their gene-expression profiles [33,34]. TG2
expression was confined to some basal A and all basal B




+ luminal types (Figure 1a).
Next, we measured IL-6 production from breast cancer
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a high level of TG2 produced a large amount of IL-6.
Some breast cancer cells neither expressed TG2 nor
produced IL-6 (Figure 1b).
TG2-knockdown reduced IL-6 production in breast cancer
cells
To evaluate whether modulation of TG2 expression levels
in the given cancer cells leads to a change in IL-6 produc-
tion, we compared IL-6 levels in control empty vector-
transfected TG2 high-expressing cells, MDA-MB-231
(cont_MB231), and their TG2-knocked-down cells by
using shRNA vectors (shTG2_MB231; Figure 2a).
shTG2_MB231 showed reduced IL-6 production, com-
pared with cont_MB231 (Figure 2b). A causal link between
TG2 activity and IL-6 production was confirmed by using
the TG2 inhibitor cysteamine. Inhibition of TG2 enzy-
matic activity reduced IL-6 production from TG2-high-
expressing cells (Figure 2c). These findings indicate that
TG2 is a key regulator of IL-6 production in breast cancer
cells. We also established IL-6-knocked-down breast can-
cer cells (shIL-6_MB231) by using the shIL-6 vector. The
shIL-6_MB231 showed reduced IL-6 secretion, but
revealed TG2 expression levels comparable to those of
control cells (Figure 2d). Thus IL-6 production was down-
stream of TG2 activity in the breast cancer cells.
Figure 1 TG2 expression levels in cancer cells correlated with IL-6 production. (a) TG2 expression in the 13 indicated human breast cancer
cell lines was analyzed with Western blot. (b) IL-6 levels in culture supernatants of breast cancer cells were determined with enzyme-linked
immunosorbent assay (ELISA). 1 × 10
4 cells were applied on 24-well plates and allowed to adhere overnight. Then the medium was replaced,
and cells were permitted to grow for 24, 48, or 72 h. Data represent mean ± SD, based on three independent experiments using samples from
triplicate cell cultures. IL-6, interleukin 6; SD, standard deviation; TG2, transglutaminase 2.
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dependent on TG2-mediated IL-6 expression
TG2 expression endows aggressiveness and invasiveness
to cancer cells through multiple effector pathways [35].
As tumor sphere formation and tumor cell aggressive-
ness are correlated [36] and IL-6 in tumor cells triggers
malignant features in tumor spheres [15], we evaluated
whether TG2 and downstream IL-6 were involved in
tumor-sphere formation in vitro. Sphere formation
decreased markedly both in TG2-knocked-down and IL-
6-knocked-down breast cancer cells (shTG2_MB231#1
and shIL-6_MB231#6, respectively) compared with the
control empty vector-transfected cells (Figure 3a and
3b). The numbers and sizes of the spheres were reduced
both in TG2-knocked-down and IL-6-knocked-down
cells (Figure 3a and 3b). Compared with TG2-knocked-
down cells (shTG2_MB231#1), control cancer cells
(cont_MB231) cultured in sphere medium expressed
more antiapoptotic molecules, such as cIAP2 and Bcl-2
(Figure 3c). These data indicate that TG2 supported cell
survival in an anchorage-independent condition. In addi-
tion, control cancer cells expressed more epithelial-to-
Figure 2 TG2-knocked-down breast and ovarian cancer cells secreted less IL-6. (a) MDA-MB-231 human breast cancer cells were stably
transfected with shRNAs targeting TG2. The efficiency of knockdown was assessed with Western blot. (b) IL-6 levels in the culture supernatants
of control and TG2-knocked-down MDA-MB-231 cells were determined with ELISA. (c) Effect of the TG2 inhibitor cysteamine (CyM) on IL-6
secretion in control MDA-MB-231 cells was determined with ELISA. (d) MDA-MB-231 cells were stably transfected with shRNAs targeting IL-6. The
efficiency of knockdown was verified by measuring IL-6 levels in the culture supernatants. TG2 expression of control and IL-6-knocked-down
MDA-MB-231 cells was analyzed with Western blot. (b-d) 1×1 0
4 cells were applied on 24-well plates and allowed to adhere overnight. Then
the medium was replaced, and cells were permitted to grow for 24 or 48 h (b, c) or for 48 h only (d). Data represent mean ± SD, based on
three independent experiments using samples from triplicate cell cultures. IL-6, interleukin 6; SD, standard deviation; TG2, transglutaminase 2.
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as N-cadherin and vimentin, compared with either
TG2-knocked-down (shTG2_MB231#1) or IL-6-
knocked-down cells (shIL-6_MB231#6) (Figure 3d).
TG2 and downstream IL-6 facilitate tumor growth and
distant liver and lung metastasis of breast cancer cells
Previous results demonstrated that high TG2 expression
resulted in high IL-6 expression, which was correlated
with increased anchorage-independent growth. To eval-
uate the role of TG2 and downstream IL-6 in tumor
cell behavior in vitro, the effect of TG2 and its down-
stream IL-6 on in vivo tumor spreading and distant
metastasis was evaluated by using highly immunocom-
promised NOD/scid/IL-2Rg chain-deficient (NOG) mice,
which completely lack NK activity, as well as T- and B-
cell activity, as recipients [37].
Breast cancer cells with high TG2 levels (cont_MB231)
showed rapid growth of primary tumor masses in the
mammary fatpads compared with TG2-knocked-down
cells (shTG2_MB231#1, Figure 4a and 4c) and IL-6-
knocked-down cells (shIL-6_MB231#6, Figure 4b and
4c). Notably, all the mice injected with IL-6-knocked-
down cells showed no tumor mass formation at all in the
fatpads up to 45 days after tumor inoculation (Figure 4b
and 4c). More interestingly, our highly immunocompro-
mised NOG mice inoculated with TG2-high-expressing
cont_MB231 showed spontaneous distant hematogenous
metastases, revealing multiple visible tumor masses in
the lung parenchyma (Figure 4d). In contrast, much
reduced lung metastasis was noted from mice injected
with TG2-knocked-down cells (shTG2_MB231#1), and
no metastasis, with IL-6-knocked-down cells (shIL-
6_MB231#6) (Figure 4d).
TG2 expression predicted recurrence and metastasis in
patients with breast cancer
The clinical implications of TG2 expression in human
breast cancer primary tumor tissue were examined with
a tissue microarray from 443 patients with operable
breast cancer treated at Seoul National University Hos-
pital between February 2000 and December 2002.
Among them, 31 patients were excluded because their
microarray core did not contain breast tumor tissue or
the tissue was detached during the immunostaining pro-
cess, leaving 412 patients for the final analysis. The
mean follow-up duration was 83.6 months (± 29.8
months). Forty-two (10.2%) patients showed strong TG2
expression, compared with control endothelial cells (Fig-
ure 5a). The TG2 expression level was not significantly
associated with known breast cancer prognostic factors,
such as tumor size, lymph node metastasis, age, or
estrogen-receptor status (Additional file 1 Table S1).
However, patients with TG2-upregulated tumors had
significantly shorter recurrence-free survival and distant
metastasis-free survival (P = 0.019 and P = 0.006,
respectively; Figure 5b and 5c) than those who did not.
The TG2 expression level remained an independent
prognostic factor predicting recurrence and distant
metastasis after adjusting for known prognostic factors
by using a Cox proportional hazard model (Figure 5d).
These findings suggest that TG2 in human breast cancer
primary tumor may play a critical role in cancer cell
metastasis and recurrence.
Figure 3 TG2-mediated IL-6 allows anchorage-independent survival of cancer cells. (a) Control and TG2-knocked-down MDA-MB-231 cells
were cultured in serum-free medium consisting of a 1:1 mixture of Ham F-12 and DMEM, supplemented with growth factors. Visible spheres
were counted under a microscope on day 8 after plating. Data represent mean ± SD based on three independent experiments using samples
from triplicate cell cultures. (b) Phase-contrast microscopy of day 8 spheres generated from the MDA-MB-231 cell line. Data shown are
representatives of three independent experiments. (c) cIAP2 and Bcl-2 expression was analyzed with Western blot after culture for the indicated
time in sphere medium. (d) TG2, fibronectin (FN), N-cadherin (N-Cad), and vimentin expression of control, TG2-knocked-down, and IL-6-knocked-
down MDA-MB-231 cells analyzed with Western blot. IL-6, interleukin 6; SD, standard deviation; TG2, transglutaminase 2.
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expression of TG2 and IL-6 was correlated and that
high TG2 expression was associated with a high propor-
tion of distant metastasis and larger primary tumors in
a mouse xenograft model. To confirm this relation in
patient clinical data, public datasets that included a total
of 684 breast cancer patients were collected, and the
association between DMFS and TG2/IL-6 expression
Figure 4 TG2-knocked-down and IL-6-knocked-down breast cancer cells revealed decreased tumor formation and distant metastasis.
(a) Control and TG2-knocked-down MDA-MB-231 cells (2 × 10
5 cells/each mouse) were injected in the fatpads of NOG mice. The growth of
primary tumors was measured. (b) Control and IL-6-knocked-down MDA-MB-231 cells (2 × 10
5 cells/each mouse) were injected in the fatpads of
NOG mice. The growth of primary tumors was measured. (a, b) Data are given as mean ± SD of 14 mice for each group from two independent
experiments. (c, d) At 45 days after the inoculation of cancer cells, the mice were killed, and the primary tumor masses in the fatpads and
distant metastases in the liver, lung, and other organs were analyzed. (c) Tumor formation in the fatpads of mice xenografted with MDA-MB-231
cells. (d) Lung sections from mice xenografted with MDA-MB-231 cells were obtained and stained with hematoxylin and eosin (original
magnification, ×200). (c, d) Data shown are representatives of each group. IL-6, interleukin 6; NOG, NOD/scid/IL-2Rg chain-deficient; SD, standard
deviation; TG2, transglutaminase 2.
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three groups based on the level of IL-6 expression: high
(patients with ≥67% IL-6 expression), medium
(33~67%), and low IL-6 (≤33%) (Figure 6a). Subse-
quently, the patients in each group were further strati-
fied into two groups according to the level of TG2
expression: low TG2 included patients with ≤33%
expression level of TG2, and high TG2 included all
other patients (Figure 6b). Finally, the survival analysis
revealed that in the high IL-6 group, most of the
patients expressed high levels of TG2 (n =1 8 1 ) ,a n d
only 20% of the patients (n = 45) expressed low levels of
TG2 (Figure 6c). In addition, high TG2 was associated
with a significantly (P = 0.013) shorter DMFS compared
with low TG2 in this group. However, no significant
survival differences were detected between the high- and
low-TG2 groups in the low- or medium-IL-6 groups
(Figure 6d and 6e). Conversely, the proportion of
patients with low TG2 expression increased as the
expression of IL-6 decreased (Figure 6c through 6e),
indicating that the expression of TG2 and IL-6 is also
correlated in breast cancer patients. In conclusion, com-
bined high expression of TG2 and IL-6 was related to a
poor DMFS outcome in breast cancer.
Discussion
Tumor metastasis is one of the most serious and rele-
vant problems in tumor treatment. The formation of
Figure 5 TG2 expression predicts recurrence and meta s t a s i si np a t i e n t sw i t hb r e a s tc a n c e r . TG2 expression was analyzed with
immunohistochemistry in a tissue microarray of primary tumors from patients with advanced breast cancer. (a) Immunohistochemical staining
for TG2 in the primary tumors of patients with breast cancer showing negative (upper) and strong expression (lower) (×200). (b) Recurrence-free
survival and (c) distant metastasis-free survival according to TG2 expression adjusted for tumor size (≤2 cm versus > 2 cm), histologic grade (1, 2
versus 3), lymph node status (positive versus negative), and hormone-receptor status (positive versus negative). The mean follow-up duration for
patients after surgery was 83.6 ± 29.8 months. (d)/////Table 1. Cox’s proportional hazards regression models for recurrence-free and distant
metastasis-free survival. TG2, transglutaminase 2.
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action of various effectors not yet completely identified.
In this study, we found that TG2 expression in tumor
cells is essential for tumor growth, invasion, and distant
hematogenous metastasis. Furthermore, a tissue micro-
array analysis of 412 patients with advanced breast can-
cer and a 7-year follow-up revealed that TG2 expression
in primary tumor tissue is correlated with recurrence-
free survival and distant metastasis-free survival.
Cancer-sphere formation is an in vitro assay to detect
a cancer cell subpopulation that shows anchorage-inde-
pendent growth in vitro and in vivo tumorigenesis [15],
called cancer-initiating cells. For distant metastasis,
detached cells from the tumor microenvironments enter
the circulation. The survival of circulating cells is
affected by inflammatory cytokines, such as tumor
necrosis factor alpha (TNF-a) and IL-6 [38]. TNF-a has
controversial effects in cancer pathogenesis, including
induction of apoptosis or EMT of tumor cells [39,40].
IL-6 is produced from epithelial tumor cells themselves
as well as stromal cells, and cancer-derived IL-6 induces
a cancer stem cell-like phenotype in these cells [15].
Moreover, sustained activation of STAT3, a downstream
IL-6 signaling mediator, is important for stem cell self-
renewal [41,42].
In this study, in vitro tumor-sphere formation of
breast cancer cells was largely dependent on TG2
expression and was inhibited by a TG2 enzymatic inhi-
bitor. IL-6 production from cancer cells was dependent
on TG2 expression, and tumor-sphere formation was
correlated with TG2-dependent IL-6 production in can-
cer cells, indicating that the effect of TG2 on tumor-
sphere formation is mediated through downstream IL-6
production. A correlation between in vitro tumor-sphere
Figure 6 Expression of TG2 and IL-6 in patients with breast cancer and their relation to distant metastasis-free survival.I nt o t a l ,6 8 4
human breast cancer gene-expression profiles were obtained from three public datasets, and the association between the expression of TG2/IL-
6 and distant metastasis-free survival (DMFS) was analyzed. The distributions of the log2 expression levels of IL-6 (a) and TG2 (b). DMFS
according to TG2 expression in the patients with high (c), medium (d), and low (e) IL-6 expression. IL-6, interleukin 6; TG2, transglutaminase 2.
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breast cancer cells, and TG2 expression and down-
stream IL-6 production were profoundly correlated with
primary tumor growth of the human breast cancer cells
in the mammary fatpads.
In vivo tumor invasion and metastasis of epithelial
cancer cells has recently been associated with EMT of
tumor epithelial cells [43]. TGF-b and downstream
Snails, Twists, and ZEBs are associated with EMT phe-
notypes [44]. IL-6 has also been implicated in the induc-
tion of the breast cancer cell EMT phenotype [14], and
recent reports suggest the role of TG2 in the EMT phe-
nomena of both breast and ovarian cancer cells [27,28].
T h u s ,T G 2a n dd o w n s t r e a mI L - 6m a yb ei m p o r t a n ti n
the EMT of epithelial cancer cells and associated with
in vivo invasiveness and distant metastasis of these cells.
With the advantage of using highly immunocompro-
mised mice, we constructed a spontaneous distant
metastasis model by using TG2-high-expressing MDA-
MB-231 human breast cancer cells implanted in the
orthotopic mammary fatpads. Forty-five days after
implantation of control MDA-MB-231 cells, all the mice
showed visible lung metastases. Lung metastases were
decreased in the mice xenografted with TG2-knocked-
down cells, and none of the mice xenografted with IL-6-
knocked-down cells showed distant metastases. Thus
TG2 and downstream IL-6 produced from epithelial
breast cancer cells facilitated distant hematogenous lung
metastases of these cells.
In this study, the TG2 and downstream IL-6 signaling
pathway may act as a convergence site for EMT and can-
cer-initiating cell phenotypes, leading to enhanced local
tumor growth and distant hematogenous metastasis.
Thus, targeting either TG2 or downstream IL-6 would be
a very efficient strategy to inhibit primary tumor growth
and distant hematogenous metastasis of breast cancer
cells. Complete inhibition of primary tumor growth and
distant lung metastasis by IL-6-knockdown compared
with some residual tumor growth and metastases by
TG2-knockdown in the breast cancer cells. In addition to
the IL-6 signaling pathway, TG2 can directly modulate
the extracellular matrix (ECM) structure [45], activate
focal adhesion kinase via binding with integrins [35], and
activate growth factors such as TGF-b [46], a key inducer
of EMT, buried in the ECM networks, and thus may
affect a broader aspect of tumor biology.
The clinical significance of TG2 expression in breast
cancer has been reported; TG2 is upregulated in epithe-
lial and stromal cells of tumor tissue [47], and lymph
node metastatic tumors show significantly higher TG2
expression levels than do primary tumors in the same
patients [48]. In patients with ovarian cancer, TG2 is
upregulated in cancer tissue compared with the normal
counterpart [25], and TG2 overexpression is associated
with high tumor stage [49]. However, a direct clinical
correlation between TG2 expression in primary tumor
and distant metastasis in patients is not available.
In this study, we assessed the correlation between
TG2 expression in primary breast cancer tissue and dis-
tant metastasis by analyzing a tissue microarray of 412
patients and their metastasis status for approximately 7
years (mean follow-up duration, 83.6 ± 29.8 months).
Although the overall survival rate of breast cancer
patients did not correlate with TG2 expression levels,
patients with TG2-upregulated tumors showed signifi-
cantly shorter relapse-free survival and distant metasta-
sis-free survival, after adjusting for known prognostic
factors such as tumor size, lymph node metastasis, age,
and hormone-receptor status. Thus, TG2 was an inde-
pendent prognostic factor predicting recurrence and dis-
tant metastasis in patients with breast cancer. As
increased TG2 expression has also been reported in
metastatic tumor tissue [48], we propose that TG2 is an
important mediator and/or prognostic marker for dis-
tant metastasis, affecting both cancer-initiating cell-like
and EMT phenotypes. Thus, intervention specific to
TG2 in epithelial cancer cells could provide a promising
means of controlling tumor metastasis.
Conclusions
We have observed that differential TG2 expressions of
cancer cells were dictated into their IL-6 production,
and TG2 and downstream IL-6 production from cancer
cells wase correlated with their capacity for tumor-
sphere formation in vitro. Primary tumor growth in the
mammary fatpads and distant hematogenous metastasis
of breast cancer cells into the lung was also dependent
on TG2 and downstream IL-6 expression levels. We
also found that TG2 expression in primary tumor tissue
is inversely correlated with recurrence-free survival (P =
0.019) and distant metastasis-free survival (P = 0.006) in
patients with advanced breast cancer. Thus, TG2
expression in cancer cells is an important link in IL-6-
mediated tumor aggressiveness, and TG2 could be an
important mediator of distant metastasis, both in a
xenograft animal model and in patients with advanced
breast cancer.
Additional material
Additional file 1: Table S1. Association between TG2 expression and
other clinicopathologic factors.
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